ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending and presenting at the following upcoming investor conference:

Leerink Global Healthcare Conference
Presenter: Sylvia Cheung, Chief Financial Officer
Presentation date and time: March 11, 2025 at 3:00pm ET
Location: Miami Beach, FL

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institution to request meetings.

A live webcast of the fireside chat can also be accessed by visiting the Oculis website on the Events and Presentations section under Investors & Media.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts
Ms. Sylvia Cheung, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
This email address is being protected from spambots. You need JavaScript enabled to view it.